Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction

Results of a multicenter European study

François Giuliano, Francesco Montorsi, Vincenzo Mirone, Dominique Rossi, Michael Sweeney

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Purpose: Intracavernous injection is a well established medical therapy for erectile dysfunction. We assessed the rate of success when patients with erectile dysfunction who were effectively treated with intracavernous injections of prostaglandin E1 were changed to oral therapy with sildenafil citrate. Materials and Methods: Only patients effectively managing erectile dysfunction by the intracavernous injection of 20μg. or less prostaglandin E1 for more than 6 months were eligible for study enrollment. After a 4-week run-in phase while intracavernous prostaglandin E1 therapy continued and a 48-hour washout period 176 patients with erectile dysfunction received open label sildenafil orally for 12 weeks. Satisfaction with treatment was evaluated by the 11-item erectile dysfunction index of treatment satisfaction questionnaire. A successful change to sildenafil was prospectively defined as a questionnaire score of 0 to 100 after sildenafil that was greater than or equal to the score after intracavernous prostaglandin El. Results: Of the 176 patients 69% (95% confidence limit 62 to 76) successfully changed from intracavernous prostaglandin E1 injections to oral sildenafil and elected to continue oral treatment. Mean satisfaction score after sildenafil and prostaglandin E1 was 73.8 and 63.9, respectively (p <0.001). Only 3 patients (1.7%) discontinued therapy because of treatment related adverse events. Conclusions: More than two-thirds of the men with erectile dysfunction who were stable on intracavernous injections of 20μg. or less prostaglandin E1 successfully changed to oral sildenafil, as determined by maintained or enhanced treatment satisfaction.

Original languageEnglish
Pages (from-to)708-711
Number of pages4
JournalJournal of Urology
Volume164
Issue number3 I
Publication statusPublished - Sep 2000

Fingerprint

Alprostadil
Erectile Dysfunction
Multicenter Studies
Injections
Therapeutics
Sildenafil Citrate
Prostaglandins

Keywords

  • Alprostadil
  • Impotence
  • Patient satisfaction
  • Penile erection
  • Penis

ASJC Scopus subject areas

  • Urology

Cite this

Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction : Results of a multicenter European study. / Giuliano, François; Montorsi, Francesco; Mirone, Vincenzo; Rossi, Dominique; Sweeney, Michael.

In: Journal of Urology, Vol. 164, No. 3 I, 09.2000, p. 708-711.

Research output: Contribution to journalArticle

@article{35507180e7cf47359b8c8bfcd18f9dc1,
title = "Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: Results of a multicenter European study",
abstract = "Purpose: Intracavernous injection is a well established medical therapy for erectile dysfunction. We assessed the rate of success when patients with erectile dysfunction who were effectively treated with intracavernous injections of prostaglandin E1 were changed to oral therapy with sildenafil citrate. Materials and Methods: Only patients effectively managing erectile dysfunction by the intracavernous injection of 20μg. or less prostaglandin E1 for more than 6 months were eligible for study enrollment. After a 4-week run-in phase while intracavernous prostaglandin E1 therapy continued and a 48-hour washout period 176 patients with erectile dysfunction received open label sildenafil orally for 12 weeks. Satisfaction with treatment was evaluated by the 11-item erectile dysfunction index of treatment satisfaction questionnaire. A successful change to sildenafil was prospectively defined as a questionnaire score of 0 to 100 after sildenafil that was greater than or equal to the score after intracavernous prostaglandin El. Results: Of the 176 patients 69{\%} (95{\%} confidence limit 62 to 76) successfully changed from intracavernous prostaglandin E1 injections to oral sildenafil and elected to continue oral treatment. Mean satisfaction score after sildenafil and prostaglandin E1 was 73.8 and 63.9, respectively (p <0.001). Only 3 patients (1.7{\%}) discontinued therapy because of treatment related adverse events. Conclusions: More than two-thirds of the men with erectile dysfunction who were stable on intracavernous injections of 20μg. or less prostaglandin E1 successfully changed to oral sildenafil, as determined by maintained or enhanced treatment satisfaction.",
keywords = "Alprostadil, Impotence, Patient satisfaction, Penile erection, Penis",
author = "Fran{\cc}ois Giuliano and Francesco Montorsi and Vincenzo Mirone and Dominique Rossi and Michael Sweeney",
year = "2000",
month = "9",
language = "English",
volume = "164",
pages = "708--711",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3 I",

}

TY - JOUR

T1 - Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction

T2 - Results of a multicenter European study

AU - Giuliano, François

AU - Montorsi, Francesco

AU - Mirone, Vincenzo

AU - Rossi, Dominique

AU - Sweeney, Michael

PY - 2000/9

Y1 - 2000/9

N2 - Purpose: Intracavernous injection is a well established medical therapy for erectile dysfunction. We assessed the rate of success when patients with erectile dysfunction who were effectively treated with intracavernous injections of prostaglandin E1 were changed to oral therapy with sildenafil citrate. Materials and Methods: Only patients effectively managing erectile dysfunction by the intracavernous injection of 20μg. or less prostaglandin E1 for more than 6 months were eligible for study enrollment. After a 4-week run-in phase while intracavernous prostaglandin E1 therapy continued and a 48-hour washout period 176 patients with erectile dysfunction received open label sildenafil orally for 12 weeks. Satisfaction with treatment was evaluated by the 11-item erectile dysfunction index of treatment satisfaction questionnaire. A successful change to sildenafil was prospectively defined as a questionnaire score of 0 to 100 after sildenafil that was greater than or equal to the score after intracavernous prostaglandin El. Results: Of the 176 patients 69% (95% confidence limit 62 to 76) successfully changed from intracavernous prostaglandin E1 injections to oral sildenafil and elected to continue oral treatment. Mean satisfaction score after sildenafil and prostaglandin E1 was 73.8 and 63.9, respectively (p <0.001). Only 3 patients (1.7%) discontinued therapy because of treatment related adverse events. Conclusions: More than two-thirds of the men with erectile dysfunction who were stable on intracavernous injections of 20μg. or less prostaglandin E1 successfully changed to oral sildenafil, as determined by maintained or enhanced treatment satisfaction.

AB - Purpose: Intracavernous injection is a well established medical therapy for erectile dysfunction. We assessed the rate of success when patients with erectile dysfunction who were effectively treated with intracavernous injections of prostaglandin E1 were changed to oral therapy with sildenafil citrate. Materials and Methods: Only patients effectively managing erectile dysfunction by the intracavernous injection of 20μg. or less prostaglandin E1 for more than 6 months were eligible for study enrollment. After a 4-week run-in phase while intracavernous prostaglandin E1 therapy continued and a 48-hour washout period 176 patients with erectile dysfunction received open label sildenafil orally for 12 weeks. Satisfaction with treatment was evaluated by the 11-item erectile dysfunction index of treatment satisfaction questionnaire. A successful change to sildenafil was prospectively defined as a questionnaire score of 0 to 100 after sildenafil that was greater than or equal to the score after intracavernous prostaglandin El. Results: Of the 176 patients 69% (95% confidence limit 62 to 76) successfully changed from intracavernous prostaglandin E1 injections to oral sildenafil and elected to continue oral treatment. Mean satisfaction score after sildenafil and prostaglandin E1 was 73.8 and 63.9, respectively (p <0.001). Only 3 patients (1.7%) discontinued therapy because of treatment related adverse events. Conclusions: More than two-thirds of the men with erectile dysfunction who were stable on intracavernous injections of 20μg. or less prostaglandin E1 successfully changed to oral sildenafil, as determined by maintained or enhanced treatment satisfaction.

KW - Alprostadil

KW - Impotence

KW - Patient satisfaction

KW - Penile erection

KW - Penis

UR - http://www.scopus.com/inward/record.url?scp=0033890352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033890352&partnerID=8YFLogxK

M3 - Article

VL - 164

SP - 708

EP - 711

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3 I

ER -